Table 6.

Summary of the recent studies reporting proteomics biomarker candidates differentiating patients with acute AR and stable graft function and patients with various types of cancer from healthy individualsa

Author (Reference)Method (Chip)/SampleTop Classifiers (kD) in AR or Type of CancerSensitivity (%)Specificity (%)
Proteomics in acute rejection
    Clarke et al. (13)SELDI (IMAC-3, H4) urine6.5, 6.6, 6.7, 7.1, 13.482100
    O’Riordan et al. (14)SELDI (H50, Q10, CM10, IMAC30) urine2.003, 2.8036, 4.7563, 5.8724, 6.9906, 19.0188, 25.665790.5 to 91.377.2 to 83.3
    Schaub et al. (15)SELDI (NP20) urine5.270 to 5.550, 7.050 to 7.360, 10.530 to 11.100
    Wittke et al. (16)CE-MS urine1.0276, 1.0316, 1.1686, 1.6979, 1.7078, 1.8110, 1.8138, 2.0789, 2.1211, 2.8159, 2.8389, 3.2402, 3.3596, 3.4821, 3.5161, 8.0523
    Jahnukainen et al. (this study)SELDI (CM10, IMAC30) urine4.755, 6.245, 6.440, 7.672, 8.012, 8.230, 9.636, 9.870, 10.067, 10.569, 16.91856 to 7863 to 81
Proteomics in cancer
    Vlahou et al. (11)SELDI (SAX2)/urineBladder cancer8766
    Rogers et al. (10)SELDI (WCX2)/urineRenal cancer7560 to 81.8
    Vlahou et al. (12)SELDI (SAX2, IMAC)/urineOvarian cancer84.680
  • a SELDI, surface-enhanced laser desorption/ionization.